var data={"title":"Amphotericin B deoxycholate (conventional): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphotericin B deoxycholate (conventional): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5633?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B deoxycholate (conventional): Drug information&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphotericin B deoxycholate (conventional): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7254335\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis, and esophageal candidiasis in patients with normal neutrophil counts.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Error prevention:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exercise caution to prevent inadvertent overdose with amphotericin B. Verify the product name and dosage if dose exceeds 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134687\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fungizone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045094\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Topical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432526\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection; conventional amphotericin B for injection doses should not exceed 1.5 mg/kg/day.</b> Although the manufacturer's labeling suggests a dose escalation approach; most expert recommendations initiate therapy at the target dose (Bradley 2016; <i>Red Book</i> [AAP 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>General dosing, susceptible infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 mg/kg/dose once daily (Bradley 2016; <i>Red Book</i> [AAP] 2015; Turkova 2011); rapidly progressing or severe disease may require higher doses up to 1.5 mg/kg/day for the short-term. Once therapy has been established, amphotericin B can be administered on an every-other-day basis at 1 to 1.5 mg/kg/dose       <b>Note:</b> Maintaining a sodium intake of &gt;4 mEq/kg/day in premature neonates may reduce amphotericin B-associated nephrotoxicity (Turcu 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Irrigation, bladder: Limited data available: 50 <b>mcg</b>/mL solution, administered as either a continuous irrigation or as an intermittent irrigation 3 times per day with a dwell time of 60 to 90 minutes; dosing based on two case reports in neonates [PNA at treatment: 3 weeks; 3 months (PCA: 42 weeks)] (Ku 2004; Martinez-Pajares 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): Limited data available; some dosing based on experience in older pediatric patients: 0.01 to 1 mg; frequency varies widely in the literature; administration has been reported as daily, every other day, and even twice weekly (Chiou 1994; Murphy 2000; IDSA [Pappas 2016]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Blastomycosis</i>, treatment:</b> IV: 1 mg/kg/dose once daily (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invasive, treatment: IV: 1 mg/kg/dose once daily; treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved  (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS infection: IV: 1 mg/kg/dose once daily; may add flucytosine if there is no clinical response (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urinary tract infections, asymptomatic (high-risk patients); treatment: IV: 1 mg/kg/dose once daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urologic procedures; prophylaxis in patients with candiduria: IV: 0.3 to 0.6 mg/kg/dose once daily for several days before and after procedure (IDSA [Pappas 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045086\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B deoxycholate (conventional): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection; conventional amphotericin B for injection doses should not exceed 1.5 mg/kg/day</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: Premedication:</b> For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID (with or without diphenhydramine) <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Test dose:</b> Infants, Children, and Adolescents: IV: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 20 to 60 minutes; an alternative method to the 0.1 mg/kg test dose is to initiate therapy with 0.25 mg/kg amphotericin administered over 6 hours; frequent observation of the patient and assessment of vital signs during the first several hours of the infusion is recommended; many clinicians believe a test dose is unnecessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 0.25 to 0.5 mg/kg/dose once daily; gradually increase daily, usually in 0.25 mg/kg increments until the desired daily dose is reached (maximum daily dose: 1.5 mg/kg/<b>day</b>); in critically ill patients, more rapid dosage acceleration may be warranted (eg, &ge;0.5 mg/kg daily dose increase); others have initiated at target dose for life-threatening infection (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 0.25 to 1 mg/kg/dose once daily; rapidly progressing disease may require short-term use of doses up to 1.5 mg/kg/<b>day</b>; once therapy has been established, amphotericin B may be administered on an every-other-day basis at 1 to 1.5 mg/kg/dose in some cases</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): Limited data available; dose variable: Infants, Children, and Adolescents: 0.01 to 1 mg; frequency varies widely in the literature; administration has been reported as daily, every other day and even twice weekly (Chiou 1994; IDSA [Pappas 2016]; Murphy 2000; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Irrigation, bladder: Infants, Children, and Adolescents: Limited data available: 50 <b>mcg</b>/mL solution, administered as either a continuous irrigation or as an intermittent irrigation 3 times daily with a dwell time of 60 to 90 minutes (Fisher 2011; Gubbins 1999); some experts have also recommended daily administration for 5 days for the treatment of cystitis due to fluconazole-resistant <i>Candida</i> species (<i>C. glabrata</i>, <i>C. krusei</i>) (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Aspergillosis:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis, immunocompromised: Limited data available: Infants, Children, and Adolescents: Intranasal: 7 mg amphotericin B in 7 mL sterile water was placed in a De Vilbiss atomizer and the aerosolized solution was instilled intranasally to each nostril 4 times daily delivering an average of 5 mg amphotericin/<b>day</b> to reduce the frequency of invasive aspergillosis in neutropenic patients (Jeffery 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Blastomycosis</i> (independent of HIV status), moderately severe to severe disease:</b> Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily as initial therapy for 1 to 2 weeks, followed with oral itraconazole for a total of 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis; treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive: Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose once daily; duration of therapy dependent upon severity and site of infection (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Esophageal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-exposed/-positive: </i>Infants, Children, and Adolescents: IV: 0.3 to 0.7 mg/kg/dose once daily; consider step down to an oral antifungal once patient is able to tolerate oral intake. In fluconazole-refractory disease, continue amphotericin B for 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: IV: 0.3 to 0.7 mg/kg/dose once daily (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: IV: 0.6 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oropharyngeal, fluconazole-refractory:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-exposed/-positive: </i>Infants, Children, and Adolescents: IV: 0.3 mg/kg/dose once daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: IV: 0.3 to 0.5 mg/kg/dose once daily (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescent: IV: 0.6 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Urinary tract infections (IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prophylaxis, urologic procedures in patients with candiduria: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for several days before and after procedure</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Cystitis: Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Asymptomatic (high-risk patients): 1 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Symptomatic<i> (C. krusei or fluconazole-resistant C. glabrata)</i>: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days</p>\n    <p style=\"text-indent:-4em;margin-left:14em;\">Pyelonephritis: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days; depending on organism, consider addition of flucytosine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive</i> (IDSA [Galgiani 2005]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Disseminated (non-CNS) disease: IV 0.5 to 1.5 mg/kg/dose every day or every other day; with or without concomitant azole antifungal; duration determined by clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CNS disease: Intrathecal: 0.1 to 1.5 mg/dose; frequency ranging from daily to weekly (with or without concomitant azole therapy); initiate at a low dose and increase until intolerance is noted (eg, severe vomiting, exhaustion, or transient dose-related mental status changes); duration determined by clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pulmonary disease, diffuse: IV 0.5 to 1.5 mg/kg/dose every day or every other day for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i> Disseminated (non-CNS) disease, diffuse pulmonary disease; severely ill:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 0.5 to 1 mg/kg/dose once daily until clinical improvement; minimum of several weeks of therapy (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 0.7 to 1 mg/kg/dose once daily until clinical improvement, then initiate triazole therapy (eg, fluconazole or itraconazole) (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcal disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CNS disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-exposed/-positive:</i> Infant, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily plus flucytosine; <b>Note:</b> Minimum 2- to 4-week induction, followed by consolidation and chronic suppressive therapy; may increase amphotericin dose to 1.5 mg/kg/day if flucytosine is not tolerated (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: IV: 1 mg/kg/dose once daily plus flucytosine or fluconazole; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement; may increase amphotericin dose to 1.5 mg/kg/day alone or in combination with fluconazole if flucytosine is not tolerated (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: IV: 0.7 to 1 mg/kg/dose once daily with or without flucytosine or fluconazole; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Disseminated (non-CNS disease) or severe pulmonary disease:<i> Independent of HIV status:</i> Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily with or without flucytosine; duration of therapy depends on the site and severity of the infection and clinical response (HHS [OI adult 2016]; HHS [OI pediatric 2013]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i> Severe disseminated (non-CNS) or pulmonary disease: Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily; <b>Note:</b> Minimum 1- to 2-week induction, followed by consolidation therapy (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i> CNS or severe disseminated disease: Infants and Children: IV: 0.7 to 1 mg/kg/dose once daily, followed by consolidation therapy (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of induction:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe or moderately severe pulmonary disease: 1 to 2 week minimum</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Disseminated or clinical improvement delayed: &ge;2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CNS involvement: 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis, visceral (HIV-exposed/-positive): </b>Adolescents: IV: 0.5 to 1 mg/kg/dose once daily for a total cumulative dose of 1,500 to 2,000 mg (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (CAPD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intraperitoneal, dialysate: Children: 0.5 to 2 mg per liter of dialysate; either with or without low-dose IV amphotericin B therapy (Manley 2000; Raajimakers 2007; Warady 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents: 1 mg/kg/dose once daily (Warady 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis, </b>\n      <b>severe </b>\n      <b>infection</b> (IDSA [Kauffman 2007]): Children and Adolescents: 0.7 mg/kg/dose once daily; followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Test dose:</b> IV: 1 mg infused over 20 to 30 minutes. Many clinicians believe a test dose is unnecessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Susceptible fungal infections:</b> IV: 0.3 to 1.5 mg/kg/dose once daily; 1 to 1.5 mg/kg over 4 to 6 hours every other day may be given once therapy is established; aspergillosis, rhinocerebral mucormycosis, often require 1 to 1.5 mg/kg/day; maximum daily dose: 1.5 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If renal dysfunction is due to the drug, the daily total can be decreased by 50% or the dose can be given every other day. IV therapy may take several months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal replacement therapy: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis or CRRT.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134665\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as desoxycholate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134650\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045097\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer by IV infusion over 2 to 6 hours; an in-line filter (&gt;1 micron mean pore diameter) may be used for administration (Kintzel 1992). For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen) &plusmn; diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Bolus infusion of normal saline immediately preceding, or immediately preceding and following amphotericin B may reduce drug-induced nephrotoxicity. Risk of nephrotoxicity increases with amphotericin B doses &gt;1 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irrigation solution (bladder): Administer as a continuous irrigation or intermittently with a dwell time of 60 to 90 minutes (Fisher 2011; Gubbins 1999; Ku 2004; Martinez-Pajares 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Administer intranasally via a De Vilbiss atomizer (Jeffrey 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134680\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Store intact vials under refrigeration. Protect from light. Reconstituted vials are stable, protected from light, for 24 hours at room temperature and 1 week when refrigerated. Parenteral admixtures in D5W are stable, protected from light, for 24 hours at room temperature and 2 days under refrigeration. Short-term exposure (&lt;24 hours) to light during IV infusion does <b>not</b> appreciably affect potency. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045096\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of progressive, potentially life-threatening susceptible fungal infections (FDA approved in pediatric patients [age not specified] and adults); has also been used for fungal peritonitis, irrigant for bladder fungal infections, used in fungal infection in patients with bone marrow transplantation, and chemoprophylaxis (low-dose IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134718\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Conventional amphotericin formulations (Amphocin, Fungizone) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134715\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing, hypertension, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Arachnoiditis, chills, delirium, headache (less frequent with I.T.), malaise, neuralgia (lumbar; especially with intrathecal therapy), pain (less frequent with I.T.), paresthesia (especially with intrathecal therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia, hypomagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, diarrhea, epigastric pain, heartburn, nausea (less frequent with I.T.), stomach cramps, vomiting (less frequent with I.T.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (normochromic-normocytic), leukocytosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (with or without phlebitis or thrombophlebitis [incidence may increase with peripheral infusion of admixtures])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal function abnormality (including azotemia, renal tubular acidosis, nephrocalcinosis [&gt;0.1 mg/ml]), renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Acute hepatic failure, agranulocytosis, anuria, blood coagulation disorder, bone marrow depression, bronchospasm, cardiac arrest, cardiac arrhythmia, cardiac failure, convulsions, diplopia, dyspnea, eosinophilia, exfoliation of skin, hearing loss, hemorrhagic gastroenteritis, hepatitis, hypersensitivity pneumonitis, increased liver enzymes, jaundice, leukoencephalopathy, leukopenia, maculopapular rash, melena, nephrogenic diabetes insipidus, oliguria, peripheral neuropathy, pruritus, pulmonary edema, renal failure, renal tubular acidosis, shock, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, toxic epidermal necrolysis, ventricular fibrillation, vertigo (transient), visual disturbance, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134672\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134654\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur 1 to 3 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Avoid rapid infusion to prevent hypotension, hypokalemia, arrhythmias, and shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukoencephalopathy: Has been reported following administration of amphotericin. Total body irradiation has been reported to be a possible predisposition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: May cause nephrotoxicity; usual risk factors include underlying renal disease, concomitant nephrotoxic medications and daily and/or cumulative dosing of amphotericin. Avoid use with other nephrotoxic drugs; drug-induced renal toxicity usually improves with interrupting therapy, decreasing dosage, or increasing dosing interval. However permanent impairment may occur, especially in patients receiving large cumulative dose (eg, &gt;5 g) and in those also receiving other nephrotoxic drugs. Hydration and sodium repletion prior to administration may reduce the risk of developing nephrotoxicity. Frequent monitoring of renal function is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fungal infections: <b>[US Boxed Warning]: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections, not noninvasive forms of infection.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenic patients: Pulmonary reactions may occur in neutropenic patients receiving leukocyte transfusions; separation of the infusions as much as possible is advised.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error prevention: <b>[US Boxed warning]: Verify the product name and dosage if dose exceeds 1.5 mg/kg.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Therapy interruption: If therapy is stopped for &gt;7 days, restart at the lowest dose recommended  and increase gradually.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819743\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May premedicate patients who experience mild adverse reactions with acetaminophen and diphenhydramine 30 minutes prior to the amphotericin B infusion; meperidine and ibuprofen may help to reduce fevers and chills; hydrocortisone can be added to the infusion solution to reduce febrile and other systemic reactions. If therapy is stopped for &gt;7 days, restart at the lowest dose recommended and increase gradually. Administer by slow IV infusion; rapid infusion has been associated with hypotension, hypokalemia, arrhythmias, and shock. Avoid extravasation; may cause chemical irritation; monitor infusion site; heparin 1 unit/1 mL of infusion solution can be added to reduce phlebitis. Use caution with intraperitoneal administration; use associated with irritation to the peritoneum and abdominal pain; not routinely used unless intolerance to other therapies (Warady 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298744\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134659\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12647&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B (Conventional) may enhance the cardiotoxic effect of Sodium Stibogluconate. Specifically, arrhythmia and sudden cardiac death risks may be increased. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134661\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314057\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women. Refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045093\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (monitor frequently during therapy: Every other day during dose increases and at least weekly, thereafter), electrolytes (especially potassium and magnesium), liver function tests, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc); blood pressure, temperature, pulse, respiration, IV site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134653\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134671\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Poor oral absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Minimal amounts enter the aqueous humor, bile, pericardial fluid, pleural fluid, and synovial fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS penetration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preterm neonates (GA: 27.4 &plusmn; 5 weeks): High interpatient variability; 40% to 90% of serum concentrations (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Poor (inflamed or noninflamed meninges)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">V<sub>d</sub>: Pediatric patients (0 to 18 years): Highly variable; reported range: 0.38 to 3.99 L/kg (Benson 1989; Koren 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates (GA: 27.4 &plusmn; 5 weeks): 14.8 hours (range: 5 to 82 hours) (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children (4 months to 14 years): 18.1 &plusmn; 6.6 hours (range: 11.9 to 40.3 hours) (Benson 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Biphasic: Initial: 15 to 48 hours; Terminal: 15 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Within 1 hour following a 4- to 6-hour dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (2% to 5% as biologically active form); ~40% eliminated over a 7-day period and may be detected in urine for at least 7 weeks after discontinued use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance (Benson, 1989):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children (8 months to 9 years): 0.57 &plusmn; 0.152 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (10 to 14 years): 0.24 &plusmn; 0.02 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48962369\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">Intravitreal/intracameral injection: Add 10 mL SWFI to a 50 mg vial; withdraw 1 mL of solution and further dilute with 4 mL SWFI for a concentration of 1 mg/mL. Remove 1 mL of 1 mg/mL solution and further dilute with 9 mL SWFI to achieve a final concentration of 0.1 mg/mL. A volume of 0.1 mL of the 0.1 mg/mL solution will contain 10 mcg of amphotericin. Withdraw dose into a 1 mL syringe for immediate administration (stability data are not available) (Kaushik 2001).</p>\n    <div class=\"reference\">Kaushik S, Ram J, Brar GS, Jain AK, Chakraborti A, Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. <i>Cornea</i>. 2001;20(7):715-719.<span class=\"pubmed-id\">11588423</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322986\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Amphotericin B Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $45.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134675\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amfucin (PH);</li>\n      <li>Ampho-Moronal (CH);</li>\n      <li>Amphocil (MX);</li>\n      <li>Ampholin (TH);</li>\n      <li>Amphotret (PH, TH);</li>\n      <li>Anfotericina B (DO, GT, PA);</li>\n      <li>Fungilin (QA);</li>\n      <li>Fungilin Lozenges (AU, NZ);</li>\n      <li>Fungitericin (PH);</li>\n      <li>Fungizon (CN, HN);</li>\n      <li>Fungizona (ES);</li>\n      <li>Fungizone (CH, CL, CO, DE, DK, FI, FR, GB, GR, HK, HU, IE, IN, IT, JO, KE, KR, NG, NL, PE, PL, PT, QA, SE, SI, TR, TW, TZ, UY, VE, VN, ZA);</li>\n      <li>Fungso-B (TH);</li>\n      <li>Tericin (BD);</li>\n      <li>Terix (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amphotericin B [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baley JE, Meyers C, Kliegman RM, et al, &quot;Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,&quot; <i>J Pediatr</i>, 1990, 116(5):791-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/2329429/pubmed\" target=\"_blank\" id=\"2329429\">2329429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: A scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benson JM and Nahata MC, &quot;Pharmacokinetics of Amphotericin B in Children,&quot; <i>Antimicrob Agents Chemother</i>, 1989, 33(11):1989-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/2610508/pubmed\" target=\"_blank\" id=\"2610508\">2610508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Branch RA, &quot;Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,&quot; <i>Arch Intern Med</i>, 1988, 148(11):2389-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/3056312/pubmed\" target=\"_blank\" id=\"3056312\">3056312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiou CC, Wong TT, Lin HH, et al, &quot;Fungal Infection of Ventriculoperitoneal Shunts in Children,&quot; <i>Clin Infect Dis</i>, 1994, 19(6):1049-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/7888533/pubmed\" target=\"_blank\" id=\"7888533\">7888533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eriksson U, Seifert B, and Schaffner A, &quot;Comparison of Effects of Amphotericin B Deoxycholate Infused Over 4 or 24 Hours: Randomised Controlled Trial,&quot; <i>BMJ</i>, 2001, 322(7286):579-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/11238151/pubmed\" target=\"_blank\" id=\"11238151\">11238151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher JF, Sobel JD, Kauffman CA, et al, &quot;Candida Urinary Tract Infections-Treatment,&quot; <i>Clin Infect Dis</i>, 2011, 52(Suppl 6):S457-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/21498839/pubmed\" target=\"_blank\" id=\"21498839\">21498839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al, &quot;Coccidioidomycosis,&quot; <i>Clin Infect Dis</i>, 2005, 41(9):1217-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gubbins PO, McConnell SA, and Penzak SR, &quot;Current Management of Funguria,&quot; <i>Am J Health Syst Pharm</i>, 1999, 56(19):1929-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/10554910/pubmed\" target=\"_blank\" id=\"10554910\">10554910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harbarth S, Pestotnik SL, Lloyd JF, et al, &quot;The Epidemiology of Nephrotoxicity Associated With Conventional Amphotericin B Therapy,&quot; <i>Am J Med</i>, 2001, 111(7):528-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed December 5, 2016<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imhof A, Walter RB, and Schaffner A, &quot;Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study,&quot; <i>Clin Infect Dis</i>, 2003, 36(8):943-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/12684904/pubmed\" target=\"_blank\" id=\"12684904\">12684904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeffery GM, Beard ME, Ikram RB, et al, &quot;Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,&quot; <i>Am J Med</i>, 1991, 90(6):685-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/2042684/pubmed\" target=\"_blank\" id=\"2042684\">2042684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, et al, &quot;Antifungal Therapy During Pregnancy,&quot; <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Smith GH, &quot;Practical Guidelines for Preparing and Administering Amphotericin B,&quot; <i>Am J Hosp Pharm</i>, 1992, 49(5):1156-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/1595747/pubmed\" target=\"_blank\" id=\"1595747\">1595747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, and Kavanagh RE, &quot;Administration Guidelines for Parenteral Drug Therapy. Part I: Pediatric Patients,&quot; <i>J Pharm Technol</i>, 1989, 5(3):101-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/10318297/pubmed\" target=\"_blank\" id=\"10318297\">10318297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Lau A, Klein J, et al, &quot;Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children,&quot; <i>J Pediatr</i>, 1988, 113(3):559-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/3411404/pubmed\" target=\"_blank\" id=\"3411404\">3411404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ku JH, Kim ME, Jeon YS, et al, &quot;Urinary Ascites and Anuria Caused by Bilateral Fungal Balls in a Premature Infant,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2004, 89(1):F92-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/14711869/pubmed\" target=\"_blank\" id=\"14711869\">14711869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeuticapplications. <i>Drugs</i>. 1992;44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, and Kuchta A, &quot;Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,&quot; <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manley HJ, Grabe DW, Norcross M, et al, &quot;Stability of Amphotericin B-Lipid Complex (Abelcet) in Peritoneal Dialysis Solutions,&quot; <i>Perit Dial Int</i>, 2000, 20(1):87-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/10716591/pubmed\" target=\"_blank\" id=\"10716591\">10716591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martinez-Pajares JD, Martinez-Ferriz MC, Moreno-Perez D, et al, &quot;Management of Obstructive Renal Failure Caused by Bilateral Renal Aspergilloma in an Immunocompetent Newborn,&quot; <i>J Med Microbiol</i>, 2010, 59(Pt 3):367-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/19910484/pubmed\" target=\"_blank\" id=\"19910484\">19910484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy K, Bradley J, and James HE, &quot;The Treatment of <i>Candida albicans</i> Shunt Infections,&quot; <i>Childs Nerv Syst</i>, 2000, 16(1):4-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/10672422/pubmed\" target=\"_blank\" id=\"10672422\">10672422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peleg AY and Woods ML, &quot;Continuous and 4 h Infusion of Amphotericin B: A Comparative Study Involving High-Risk Haematology Patients,&quot; <i>J Antimicrob Chemother</i>, 2004, 54(4):803-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/15308606/pubmed\" target=\"_blank\" id=\"15308606\">15308606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raaijmakers R, Schr&ouml;der C, Monnens L, et al, &quot;Fungal Peritonitis in Children on Peritoneal Dialysis,&quot; <i>Pediatr Nephrol</i>, 2007, 22(2):288-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/17111161/pubmed\" target=\"_blank\" id=\"17111161\">17111161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turcu R, Patterson MJ, and Omar S, &quot;Influence of Sodium Intake on Amphotericin B-Induced Nephrotoxicity Among Extremely Premature Infants,&quot; <i>Pediatr Nephrol</i>, 2009, 24(3):497-505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/19082636/pubmed\" target=\"_blank\" id=\"19082636\">19082636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? <i>Curr Opin Infect Dis</i>. 2011;24(2):163-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/21301335 /pubmed\" target=\"_blank\" id=\"21301335 \">21301335 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Schaefer F, Holloway M, et al, &quot;Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,&quot; <i>Perit Dial Int</i>, 2000, 20(6):610-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/11216549/pubmed\" target=\"_blank\" id=\"11216549\">11216549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al, &quot;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(7):807-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiest DB, Maish WA, Garner SS, el-Chaar GM. Stability of amphotericin B in four concentrations of dextrose injection. <i>Am J Hosp Pharm</i>. 1991;48(11):2430-2433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-pediatric-drug-information/abstract-text/1746578 /pubmed\" target=\"_blank\" id=\"1746578 \">1746578 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12647 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7254335\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134687\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045094\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432526\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045086\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134665\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134650\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045097\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F134680\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045096\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134718\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134715\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134672\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134654\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819743\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298744\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134659\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134661\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314057\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045093\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134653\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134671\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F48962369\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322986\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134675\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12647|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate (conventional): Drug information</a></li><li><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-patient-drug-information\" class=\"drug drug_patient\">Amphotericin B deoxycholate (conventional): Patient drug information</a></li></ul></div></div>","javascript":null}